



NEONATAL MEDICATION GUIDELINE

Adrenaline (Epinephrine) – Circulatory Support

Scope (Staff): Nursing, Medical and Pharmacy Staff

Scope (Area): KEMH NICU, PCH NICU, NETS WA,

This document should be read in conjunction with the [Disclaimer](#).

Quick Links

[Dose](#)

[Preparation & Administration](#)

[Side Effects & Interactions](#)

[Monitoring](#)

Restrictions

[Formulary: Restricted](#)

Requires Neonatologist or relevant specialist review within 24 hours of initiation.

HIGH RISK Medication

There are 2 presentations of adrenaline ampoules. Incorrect administration can cause dosing errors

- adrenaline (epinephrine) **1 in 1000** (1mg/1mL) **1 mL**
- adrenaline (epinephrine) **1 in 10,000** (1mg/10mL) **10mL**

Extravasation may cause tissue necrosis, monitor access site and peripheral perfusion.

Description

Nonselective adrenergic agonist. Positive inotrope and chronotrope; vasodilator at low dose; vasoconstrictor at high dose. Bronchial smooth muscle relaxant.

Presentation

Ampoule: 1 in 1000 (1mg/1mL) **1 mL**

Storage

Store at room temperature, below 25°C

Dose

Hypotension & low cardiac output

IV Infusion:

Initially 0.1 microgram/ kg/ minute then titrate according to response

Maximum of 1 microgram/ kg/ minute

Preparation

IV Infusion: Available from CIVAS (KEMH/PCH)

If unavailable prepare the below solution:

Dilution

Dilute 0.3mg (0.3mL of adrenaline 1:1000) of adrenaline per kg of baby's weight to 50mL with a compatible fluid.

Concentration:

0.2mL/hour = 0.02 microgram/ kg / minute

1mL/hour = 0.1 microgram/ kg / minute

Administration

Continuous intravenous infusion

Administer via syringe driver

Compatible Fluids

Glucose 5%, Glucose 10%, Sodium Chloride 0.9%

Y-Site Compatibility

Refer to KEMH Neonatal Medication Guideline: [Y-Site IV Compatibility in Neonates](#)

Side Effects

Common: tachycardia, tremor, hyperglycaemia

Serious: peripheral ischaemia and necrosis at infusion site, overdose or rapid administration can lead to excessive increase in blood pressure, cerebral haemorrhage, renal vascular ischemia, pulmonary oedema.

Interactions

Interaction

Monitoring

- ECG monitoring
- Continuous cardiac monitoring
- Intra-arterial blood pressure
- Observe intravenous site for signs of extravasation, and necrosis
- Peripheral perfusion/blanching
- Urinary output
- Acid base balance (can cause metabolic acidosis with prolonged use)

Comments

Adrenaline is sensitive to light and air, protection from light is recommended.
Correct acidosis prior to administration to enhance effectiveness
Contraindicated in arrhythmia, pheochromocytoma, thyrotoxicosis, glaucoma

Related Policies, Procedures & Guidelines

WNHS Clinical Practice Guidelines:

[CAHS Cardiac: Neonatal Circulation Changes / Unbalanced Circulation](#)









References

Takemoto CK, Hodding JH, Kraus DM. Pediatric & neonatal dosage handbook with international trade names index : a universal resource for clinicians treating pediatric and neonatal patients. 27th ed. Hudson (Ohio): Lexicomp; 2021. p878

Truven Health Analytics. Epinephrine. In: NeoFax [Internet]. Greenwood Village (CO): Truven Health Analytics; 2022 [cited 2022 Jun 13]. Available from: <https://neofax.micromedexsolutions.com/>

Australian Medicines Handbook. Adrenaline. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2022 [cited 2022 Jun 13]. Available from: <https://amhonline.amh.net.au/>

Adrenaline (Epinephrine) – Circulatory Support

| | | | | | |
|---|---|----------------|---|--------------|------------|
| Document Owner: | Head of Department - Neonatology | | | | |
| Author/ Reviewer | KEMH & PCH Pharmacy/Neonatology Directorate | | | | |
| Version Info: | 4.0 | | | | |
| Date First Issued: | 2013 | Last Reviewed: | 16/09/2022 | Review Date: | 16/09/2022 |
| Endorsed by: | Neonatal Directorate Management Group | | | Date: | 27/09/2022 |
| NSQHS Standards Applicable: | <input checked="" type="checkbox"/>  Std 1: Clinical Governance <input type="checkbox"/>  Std 2: Partnering with Consumers <input type="checkbox"/>  Std 3: Preventing and Controlling Healthcare Associated Infection <input checked="" type="checkbox"/>  Std 4: Medication Safety | | <input type="checkbox"/>  Std 5: Comprehensive Care <input type="checkbox"/>  Std 6: Communicating for Safety <input type="checkbox"/>  Std 7: Blood Management <input type="checkbox"/>  Std 8: Recognising and Responding to Acute Deterioration | | |
| Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint. | | | | | |

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2020

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.